Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Xencor Inc (NASDAQ:XNCR)

17.63
Delayed Data
As of Sep 02
 +1.03 / +6.20%
Today’s Change
9.00
Today|||52-Week Range
24.82
+9.91%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$671.8M

Company Description

Xencor, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. The company uses proprietary XmAb technology platform to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, asthma, cancer, and other conditions. Xencor was founded Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Contact Information

Xencor, Inc.
111 West Lemon Avenue
Monrovia California 91016
P:(626) 305-5900
Investor Relations:
(626) 737-8013

Employees

Shareholders

Other institutional47.49%
Mutual fund holders32.87%
Individual stakeholders31.33%

Top Executives

Bassil I. DahiyatPresident, Chief Executive Officer & Director
John J. KuchVice President-Finance & Investor Relations
John R. DesjarlaisChief Scientific Officer & Senior VP-Research
Paul A. FosterChief Medical Officer
Lloyd A. RowlandSecretary, Chief Compliance Officer & SVP